Stories about Krankheit

Follow
Subscribe to Krankheit
Filter
  • 17.08.2020 – 11:26

    Technische Universität München

    Designed bacteria produce coral-antibiotic

    TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36204/ High resolution images: https://mediatum.ub.tum.de/1554685 NEWS RELEASE Sustainable biotechnological production of a natural substance against tuberculosis Designed bacteria produce coral-antibiotic Corals growing on the reefs of ...

  • 06.07.2020 – 13:52

    Technische Universität München

    Gut bacteria improve type 2 diabetes risk prediction

    TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36118/ Images for journalists: https://mediatum.ub.tum.de/1552269 NEWS RELEASE Large-scale study with more than 4000 participants at ZIEL - Institute for Food & Health Gut bacteria improve type 2 diabetes risk ...

  • 02.07.2020 – 14:26

    Technische Universität München

    Nutrition in the days of COVID

    TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36110/ Images for journalists: https://mediatum.ub.tum.de/1552085 NEWS RELEASE An interview with Prof. Hans Hauner about COVID-19 and nutritional medicine Nutrition in the days of COVID The current Corona outbreak affects nearly all aspects of medicine and of everyday ...

  • 23.06.2020 – 15:58

    IgNova GmbH

    IgNova files patent application on antibody against COVID-19

    Visbek, Germany (ots) - IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (IgY). The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus when it enters the mouth or nose and, therefore, inhibiting the ...